Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...
Eli Lilly LLY announced that the phase III BRUIN CLL-313 study, evaluating its BTK inhibitor Jaypirca (pirtobrutinib) versus chemoimmunotherapy (bendamustine plus rituximab) in treatment-naïve ...
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy. People with CLL have a higher risk of developing skin cancers, including SCC, explained ...
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) The ...
A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential ...
James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma (PCNSL), stating the company ...
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...
The US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for ofatumumab (Arzerra, Genmab/Novartis) for its use in combination with fludarabine and ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results